Drug Profile

PSMA B ligand - Shuttle Diagnostics

Alternative Names: PSMA-B-Ligand

Latest Information Update: 17 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shuttle Pharmaceuticals
Developer Shuttle Diagnostics
Class Antineoplastics; Diagnostic agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

10 Apr 2025 Shuttle Pharmaceuticals files for patent protection with US PTO for PSMA-Targeted PARP Inhibitor Conjugates
19 Dec 2024 Shuttle Diagnostics and University of California agree to co-develop ligand to the prostate-specific membrane antigen (PSMA) for Cancer
14 May 2024 Early research in Prostate cancer (Diagnosis) in USA (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com